| Product Code: ETC9961616 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Cancer Gene Therapy Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Cancer Gene Therapy Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Cancer Gene Therapy Market - Industry Life Cycle |
3.4 United States (US) Cancer Gene Therapy Market - Porter's Five Forces |
3.5 United States (US) Cancer Gene Therapy Market Revenues & Volume Share, By Therapy, 2021 & 2031F |
3.6 United States (US) Cancer Gene Therapy Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 United States (US) Cancer Gene Therapy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in the US |
4.2.2 Growing investments in research and development of gene therapy |
4.2.3 Technological advancements in gene editing tools |
4.2.4 Favorable regulatory environment supporting gene therapy development |
4.3 Market Restraints |
4.3.1 High cost of gene therapy treatments |
4.3.2 Safety concerns and potential side effects of gene therapy |
4.3.3 Limited availability and accessibility of gene therapy treatments |
4.3.4 Ethical considerations and public perception of gene editing technologies |
5 United States (US) Cancer Gene Therapy Market Trends |
6 United States (US) Cancer Gene Therapy Market, By Types |
6.1 United States (US) Cancer Gene Therapy Market, By Therapy |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Cancer Gene Therapy Market Revenues & Volume, By Therapy, 2021- 2031F |
6.1.3 United States (US) Cancer Gene Therapy Market Revenues & Volume, By Gene Induced Immunotherapy, 2021- 2031F |
6.1.4 United States (US) Cancer Gene Therapy Market Revenues & Volume, By Oncolytic Virotherapy, 2021- 2031F |
6.1.5 United States (US) Cancer Gene Therapy Market Revenues & Volume, By Gene Transfer, 2021- 2031F |
6.2 United States (US) Cancer Gene Therapy Market, By End User |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Cancer Gene Therapy Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.2.3 United States (US) Cancer Gene Therapy Market Revenues & Volume, By Diagnostic centers, 2021- 2031F |
6.2.4 United States (US) Cancer Gene Therapy Market Revenues & Volume, By Research Institutes, 2021- 2031F |
7 United States (US) Cancer Gene Therapy Market Import-Export Trade Statistics |
7.1 United States (US) Cancer Gene Therapy Market Export to Major Countries |
7.2 United States (US) Cancer Gene Therapy Market Imports from Major Countries |
8 United States (US) Cancer Gene Therapy Market Key Performance Indicators |
8.1 Patient survival rates post gene therapy treatment |
8.2 Number of clinical trials for cancer gene therapy in the US |
8.3 Adoption rates of gene therapy treatments in cancer centers |
8.4 Research and development expenditures in the field of cancer gene therapy |
8.5 Number of partnerships and collaborations in the gene therapy market |
9 United States (US) Cancer Gene Therapy Market - Opportunity Assessment |
9.1 United States (US) Cancer Gene Therapy Market Opportunity Assessment, By Therapy, 2021 & 2031F |
9.2 United States (US) Cancer Gene Therapy Market Opportunity Assessment, By End User, 2021 & 2031F |
10 United States (US) Cancer Gene Therapy Market - Competitive Landscape |
10.1 United States (US) Cancer Gene Therapy Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Cancer Gene Therapy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here